Please fill out the form below and we will gladly respond as soon as possible.
Two clinical trials testing TCR-NK cell therapy for advanced synovial sarcoma are now recruiting patients, one in the United States and one in the United Kingdom. Both use donor-derived natural killer cells engineered to target proteins commonly found on synovial sarcoma tumors. What Is TCR-NK Cell Therapy? TCR-NK therapy works differently from the TCR-T cell […]
New program invites patients, survivors, caregivers, and families to turn lived experience into advocacy. [Philadelphia, PA], September 1, 2026: This Childhood Cancer Awareness Month, the Synovial Sarcoma Foundation (SSF) is inviting patients, survivors, caregivers, and supporters to take their advocacy further. SSF has officially launched its Ambassador Program, an ongoing initiative for anyone connected to […]
A study published in Cytotherapy by Kayo Toishigawa, Kenta Magoori, Hiroyuki Sato, and colleagues at Hiroshima University, in collaboration with Repertoire Genesis Inc. and Kyoto University, presents a promising new method for producing genetically engineered T cells at industrial scale using a technique called Platinum TALEN. The research is built around NY-ESO-1, one of the […]
Merck and Moderna are making headlines after their personalized mRNA cancer vaccine entered Phase 3 clinical trials for melanoma. For most people, it is an exciting medical story. For the synovial sarcoma community, it is something more personal than that. What the Vaccine Is mRNA-4157, combined with Merck’s immunotherapy pembrolizumab, works by sequencing a patient’s […]
A new preclinical study published in Biomedicine and Pharmacotherapy by Tomohiro Miyazaki, Yudai Murayama, Naoki Oike, and colleagues from the Department of Pediatrics and Division of Orthopedic Surgery at Niigata University Graduate School of Medical and Dental Sciences, Japan, presents early but promising evidence for a CAR-T cell therapy designed for synovial sarcoma that does […]
Zelluna ASA, a Norwegian biotech company pioneering allogeneic cell therapies for solid cancers, recently announced that the first patient has received the first dose of ZI-MA4-1 in the ZIMA-101 Phase 1 clinical trial. The treatment was administered at The Christie NHS Foundation Trust in Manchester, United Kingdom, the largest single-site cancer centre in Europe, marking […]
US WorldMeds® announced that the U.S. Food and Drug Administration has granted full approval to TECELRA® (afamitresgene autoleucel), with an expanded indication that now includes eligible patients as young as 12 years old. The therapy, which received its original accelerated approval in August 2024, remains the first and only FDA-approved engineered T-cell therapy for a […]
11 Leading Oncologists and Researchers Unite to Accelerate Progress for Synovial Sarcoma Patients PHILADELPHIA [June 22, 2026] The Synovial Sarcoma Foundation (SSF) today announced the formation of its Medical Advisory Board, bringing together 11 internationally recognized clinicians and researchers to serve as the central coordinating body for synovial sarcoma research, treatment, and advocacy. The board […]
A landmark study from Jerby-Arnon, Neftel, Shore, and colleagues at the Broad Institute of Harvard and MIT, Massachusetts General Hospital, Dana-Farber Cancer Institute, and the University of Lausanne used single-cell RNA sequencing to profile 16,872 individual cells from 12 human synovial sarcoma tumors – one of the most detailed cellular portraits of this disease ever […]
New industry analyses project continued growth in the North America synovial sarcoma treatment market, with a predicted compound annual growth rate (CAGR) of 4.2% from 2026 to 2033. The report reflects increasing momentum in rare cancer research, including advances in targeted therapy, immunotherapy, and precision medicine for synovial sarcoma. What’s Driving Growth in Synovial Sarcoma […]
